Tag: Herve Hoppenot
Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo
Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo with facial involvement in adults and adolescents, ... Read More
US biopharma company Incyte bags Opzelura FDA approval for vitiligo
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US Food and Drug Administration (FDA) for the ... Read More
Incyte, Innovent announce collaboration for three cancer drugs in China
US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for ... Read More